In conclusion, this is the first study to show that immunostainings for MCM2 and ACADL may be useful for identifying atypical meningiomas characterized by higher genomic instability, CDKN2A HeDe, higher integrated molecular grade, recurrence risk, and shorter RFS. This evidence concerns the gene MCM2 and meningioma.